MET and non-small cell lung carcinoma: The PROFILE 1001 study of the multi-kinase inhibitor crizotinib showed an ORR of 32% and a median PFS of 7.3 months in patients with MET exon 14 skipping NSCLC (24), and the co-MET study of crizotinib specifically in Japanese patients with NSCLC harbouring MET exon 14 skipping is ongoing (25).